Santhera Pharmaceuticals Holding AG
SANN
Company Profile
Business description
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
Contact
Hohenrainstrasse 24
Pratteln4133
CHET: +41 619068950
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
85
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
We think the positive third-quarter numbers will be largely offset by a weak fourth quarter.
stocks
ASX listed share dominates their industry
Shares are currently fairly valued with a Wide Moat rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,288.10 | 53.60 | 0.58% |
| CAC 40 | 8,081.54 | 24.91 | 0.31% |
| DAX 40 | 24,378.80 | 43.76 | -0.18% |
| Dow JONES (US) | 46,803.51 | 283.79 | 0.61% |
| FTSE 100 | 9,491.25 | 63.52 | 0.67% |
| HKSE | 27,140.92 | 146.20 | -0.54% |
| NASDAQ | 22,785.17 | 58.88 | -0.26% |
| Nikkei 225 | 45,769.50 | 832.77 | 1.85% |
| NZX 50 Index | 13,514.09 | 62.33 | 0.46% |
| S&P 500 | 6,720.34 | 4.99 | 0.07% |
| S&P/ASX 200 | 8,987.40 | 50.80 | 0.57% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |